Artizan Biosciences, Inc.

Artizan Biosciences, Inc. is a biotechnology company focused on developing innovative diagnostics and therapeutic solutions utilizing advanced genomic technologies in the microbiome space. Artizan Biosciences, headquartered in New Haven, US, was founded in 2016. The company specializes in the microbiome sector, providing insights into gastrointestinal diseases through precision medicine applications.

Marcel de Zoete is one of the founders, and Bridget Martell and James Rosen currently serve as executives. Artizan has completed a total of 4 deals, with the most recent being a Series A funding round in March 2021, raising USD 11. 00 mn from investors including Biohaven Pharmaceutical Holding Company Ltd. and Hatteras Venture Partners.

Artizan Biosciences specializes in the development of innovative diagnostics and therapeutic solutions aimed at addressing unmet medical needs within the microbiome space. Their core product offerings focus on precision medicine applications that leverage advanced genomic technologies to analyze the gut microbiome, providing insights that can influence treatment pathways for various gastrointestinal diseases. These offerings are designed for healthcare practitioners, researchers, and pharmaceutical companies, ultimately helping to enhance patient outcomes through personalized health strategies. The company serves a diverse clientele across North America and Europe, targeting markets that include clinical laboratories, academic institutions, and healthcare providers.

Artizan Biosciences generates revenue through a combination of direct-to-consumer sales and B2B partnerships with healthcare entities. Their business transactions typically involve providing diagnostic tests and related services that allow healthcare providers to offer personalized treatment recommendations based on microbiome analysis. The company’s pricing structure includes various packages for their flagship products, which are marketed to both clinical laboratories and healthcare practitioners. These services are structured around subscription models or contractual agreements that ensure ongoing access to their proprietary technology and data insights.

In March 2021, Artizan Biosciences, Inc. raised USD 11. 00 mn in Series A funding to advance preclinical research and development of its program for inflammatory bowel disease (IBD) and to explore additional disease targets. The company plans to develop new products addressing unmet medical needs in the microbiome sector, with strategic expansion into new markets in North America and Europe targeted for completion by the end of 2023.

The recent funding will enable Artizan to enhance its research capabilities and expedite the launch of innovative solutions in the diagnostic and therapeutic space.